Discover
TENX
Tenax Therapeutics, Inc.
14.33
1 x 10.83
1 x 18.24
bid
ask
+
1.04
7.83%
01:19 PM
timesize
| Ytd | 17.56% | |
| 1y | 149.65% |
14.00
day range
15.40
5.68
52 week range
18.38
| Open | 14.66 | Prev Close | 13.29 | Low | 14.00 | High | 15.40 | Mkt Cap | 380.11M |
| Vol | 2.82M | Avg Vol | 819.54K | EPS | -1.41 | P/E | N/A | Forward P/E | -1.06 |
| Beta | 2.15 | Short Ratio | 1.46 | Inst. Own | 47.95% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-15 | 50-d Avg | 12.30 | 200-d Avg | 11.34 | 1yr Est | 16.30 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-13 | 2024-09 | -1.38 | -0.19 | 1.19 | 86.23% |
| 2024-08-13 | 2024-06 | -1.99 | -1.83 | 0.16 | 8.04% |
| 2024-05-14 | 2024-03 | -2.4 | -3.12 | -0.72 | -30.00% |
| 2024-04-01 | 2023-12 | -8.15 | N/A | N/A | N/A |
| 2023-11-13 | 2023-09 | -7.2 | -6.4 | 0.8 | 11.11% |
| 2023-08-14 | 2023-06 | 0 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-10-24 | Leerink Partners | Upgrade | Outperform | |
| 2024-02-20 | Roth MKM | Upgrade | Buy | Buy |
Profile
Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-08-07 | DAVIDSON MICHAEL H | Director | 2.88K | Purchase |
| 2024-08-07 | PROEHL GERALD T | Director | 1.67K | Purchase |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | BVF Inc. | 339.55K | 1.86M | 9.96% |
| 2024-09-29 | Vivo Capital, LLC | 208.33K | 1.14M | 6.11% |
| 2024-09-29 | VR Adviser, LLC | 208.33K | 1.14M | 6.11% |
| 2024-09-29 | Velan Capital Investment Management LP | 83.33K | 457.50K | 2.44% |
| 2024-09-29 | Adage Capital Partners GP L.L.C. | 83.33K | 457.50K | 2.44% |
| 2024-09-29 | Vestal Point Capital, LP | 83.33K | 457.50K | 2.44% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Price (T.Rowe) Health Sciences Fund | 26.47K | 145.33K | 0.78% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 10.22K | 56.09K | 0.30% |
| 2024-10-30 | Fidelity Total Market Index Fund | 5.98K | 32.85K | 0.18% |
| 2024-10-30 | Fidelity Series Total Market Index Fund | 4.71K | 25.85K | 0.14% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 2.33K | 12.77K | 0.07% |
| 2024-10-30 | Fidelity NASDAQ Composite Index Fund | 364.00 | 2.00K | 0.01% |
Split
| Split | Date |
|---|---|
| 1 : 80 | 2024-01-03 |
| 1 : 20 | 2023-01-05 |
| 1 : 20 | 2018-02-26 |
| 0.05 : 1 | 2013-05-13 |
| 0.06667 : 1 | 2009-11-09 |